CATALAYER NEWS
Actuate Therapeutics CEO Daniel Schmitt purchases $49,999 in stock
Source: Investing.com · 2026-11-01
Full article text is available in the Catalayer news terminal.
MORE FROM INVESTING.COM
Citizens reiterates Kratos Defense stock rating on national security strength
2026-11-02
Citizens reiterates Ondas Holdings stock rating on IonStrike updates
2026-11-02
Why is Fresenius stock rallying today?
2026-11-02
Earnings call transcript: Lodha Developers misses Q2 2026 estimates, stock slips
2026-11-02
Why is Caixabank stock rallying today?
2026-11-02
RELATED MARKETS
Prediction Markets